Avacincaptad Pegol

DRUG11 trials

Sponsors

Astellas Pharma Global Development Inc., Ophthotech Corporation, IVERIC bio, Inc., Astellas Pharma Global Development, Inc., Astellas Pharma Inc

Conditions

Age-Related Macular DegenerationDry Age-Related Macular DegenerationGeographic AtrophyIdiopathic Polypoidal Choroidal VasculopathyMacular DegenerationNeovascular Age-Related Macular DegenerationNeovascular Age-related Macular DegenerationStargardt's Macular Dystrophy

Phase 1

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

CompletedNCT00709527

Ophthotech CorporationNeovascular Age-Related Macular Degeneration

Start: 2008-10-16End: 2009-12-30Updated: 2025-03-10

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

CompletedNCT00950638

Ophthotech CorporationDry Age-Related Macular Degeneration

Start: 2009-07-16End: 2011-03-24Updated: 2025-03-10

Phase 2

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

CompletedNCT02397954

Ophthotech CorporationIdiopathic Polypoidal Choroidal Vasculopathy

Start: 2015-03-12End: 2015-10-23Updated: 2025-03-20

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

CompletedNCT02686658

IVERIC bio, Inc.Dry Age-Related Macular Degeneration, Geographic Atrophy

Start: 2015-12-15End: 2020-04-23Updated: 2025-06-10

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

CompletedNCT03362190

Ophthotech CorporationNeovascular Age-related Macular Degeneration

Start: 2017-10-11End: 2018-10-18Updated: 2025-06-10

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

CompletedNCT03364153

Astellas Pharma Global Development, Inc.Stargardt's Macular Dystrophy

Start: 2018-01-12End: 2025-03-31Updated: 2026-03-12

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

TerminatedNCT05571267

IVERIC bio, Inc.Neovascular Age-Related Macular Degeneration

Start: 2016-10-20End: 2018-04-24Updated: 2025-03-13

Phase 3

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

CompletedNCT04435366

IVERIC bio, Inc.Geographic Atrophy, Macular Degeneration

Start: 2020-06-22End: 2023-08-22Updated: 2025-10-21

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

CompletedNCT05536297

Astellas Pharma Global Development, Inc.Age-Related Macular Degeneration, Geographic Atrophy

Start: 2022-09-26End: 2025-04-10Updated: 2026-03-18

AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)

CompletedCTIS2024-515185-13-00

Astellas Pharma Global Development Inc.geographic atrophy

Start: 2022-12-21End: 2025-04-10Target: 126Updated: 2025-03-21

Phase 4

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

RecruitingNCT06970665

Astellas Pharma IncAge-Related Macular Degeneration, Geographic Atrophy

Start: 2025-07-08End: 2027-06-30Target: 20Updated: 2026-02-27

Related Papers

Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study

BMJ Open Ophthalmology2026-02-03

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial.

2025-12-15

Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy.

2025-10-17

Progression to complete retinal pigment epithelium and outer retinal atrophy (cRORA): post hoc analysis of the GATHER1 trial.

2024-11-144 citations

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.

2023-09-08210 citations

Photoreceptor degeneration in ABCA4-associated retinopathy and its genetic correlates

JCI Insight2022-01-2424 citations

Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells.

2021-03-1037 citations